

(19)



JAPANESE PATENT OFFICE

PATENT ABSTRACTS OF JAPAN

(11) Publication number: **2000063280 A**

(43) Date of publication of application: **29.02.00**

(51) Int. Cl. <b>A61K 35/78</b> <b>A61K 31/00</b> <b>A61K 45/00</b>	
(21) Application number: <b>11164852</b> (22) Date of filing: <b>11.06.99</b> (30) Priority: <b>11.06.98 JP 10163811</b>	(71) Applicant: <b>TAKEDA CHEM IND LTD</b> (72) Inventor: <b>WATANABE MASAZUMI</b> <b>NAKAO MASAFUMI</b> <b>OKUNO KENJI</b>

**(54) ANTI-HELICOBACTER PYLORI ACTIVE  
GASTROINTESTINAL DRUG**

**(57) Abstract:**

**PROBLEM TO BE SOLVED:** To obtain a gastrointestinal drug which contains the combination of Coptidis rhizoma and/or Phellodendri cortex puerata and Aurantii nobilis pericarpium pulveratum, possesses anti-Helicobacter pylori activity and is useful in the prevention, the treatment or the recidivation prevention for gastritis, gastric ulcer, duodenal ulcer or the like.

**SOLUTION:** This gastrointestinal drug is obtained by including the combination of (A) Coptidis rhizoma and/or Phellodendri cortex pulverata or extracts and (B) Aurantii nobilis pericarpium pulveratum or extract. On this gastrointestinal drug, it is

favorable to use 2-200 pts.wt. of the raw crude drug of the component B based on 1 pt.wt. of the raw crude drug of the component A. Further, it is favorable that this gastrointestinal drug includes at least one kind of histamine H<sub>2</sub> receptor antagonist (e.g. cimetidine or the like), proton pump inhibitor (e.g. lansoprazole or the like), gastric mucosa protection type gastritis-peptic ulcer therapeutic drug (e.g. aldioxa or the like), antacid and stegnotic. On the amounts of the components A and B used, Coptidis rhizoma and Phellodendri cortex or Aurantii nobilis pericarpium are preferably used at daily doses of 0.03-6 g and 0.03-10 g, respectively, per an adult based on the raw crude drugs.

COPYRIGHT: (C)2000,JPO